Pioneering Advances in Ocular Therapy: KALA BIO, Inc. Explores New Frontiers


KALA BIO, Inc., a clinical-stage biopharmaceutical enterprise based in Arlington, Massachusetts, continues to make significant strides in the field of eye disease treatment. The organization is known for its innovative approach to developing therapies for rare and severe ocular conditions. Leveraging its proprietary mesenchymal stem cell secretome (MSC-S) platform, KALA BIO is at the forefront of biologics-based investigational therapies.

The company’s lead product candidate, KPI-012, is a human MSC-S containing a variety of human-derived biofactors, including growth factors, protease inhibitors, matrix proteins and neurotrophic factors. These components are crucial for potentially correcting the impaired corneal healing that underlies several severe ocular diseases. KPI-012 has already garnered Orphan Drug and Fast Track designations from the US Food and Drug Administration for the treatment of persistent corneal epithelial defect (PCED), a rare condition characterized by impaired corneal healing. In addition to its work on PCED, KALA BIO is exploring the potential application of KPI-012 for treating Limbal Stem Cell Deficiency and other vision-threatening corneal diseases. The organization has also initiated preclinical studies to assess the utility of its MSC-S platform for addressing retinal degenerative diseases such as Retinitis Pigmentosa and Stargardt Disease.

The ongoing CHASE Phase 2b clinical trial is a critical component of KALA BIO’s research efforts. This trial is evaluating the safety and efficacy of KPI-012 in treating PCED. Active patient enrollment and the anticipation of topline safety and efficacy data in the second half of 2024 highlight the company’s commitment to advancing its research agenda. Positive results from this trial, coupled with discussions with regulatory authorities, could position the CHASE trial as the first of two pivotal studies needed to support a Biologics License Application (BLA) submission to the FDA.

Financially, KALA BIO maintains a robust position. As of September 30, 2023, the corporation reported having $56.1 million in cash and cash equivalents. This financial stability is expected to support operations into the second quarter of 2025, aided by anticipated funding from the CIRM award. This funding framework underscores the enterprise’s strategic financial planning and resource management, which are integral to sustaining its long-term research initiatives. Moreover, KALA BIO’s commitment to its workforce is evident in its recent inducements for new employees. The company granted non-statutory stock options to new employees as a material inducement for joining the organization, demonstrating its dedication to attracting and retaining top talent, which is vital for ongoing innovation and success in the competitive biopharmaceutical landscape.

KALA BIO, Inc. continues to demonstrate its leadership in the field of biopharmaceutical research, with a strong focus on developing treatments for rare and severe diseases of the eye. Through its innovative MSC-S platform and ongoing clinical trials, the organization is not only advancing medical science but also offering hope to patients suffering from debilitating ocular diseases. As the corporation progresses with its clinical and operational endeavors, the healthcare community watches eagerly, anticipating further breakthroughs that could significantly impact ocular therapeutic practices and patient care.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button